Breast Cancer News and Research

Latest Breast Cancer News and Research

Compound in grapes and red wine may help battle obesity

Resveratrol, a compound present in grapes and red wine, reduces the number of fat cells and may one day be used to treat or prevent obesity, according to a new study. The results will be presented at The Endocrine Society's 90th Annual Meeting in San Francisco.

16 Jun 2008

Bionovo discovers new estrogen regulatory elements for breast cancer and osteoporosis drugs

Bionovo Inc. today announced results on the role of estrogen regulatory elements important in developing drugs for breast cancer and osteoporosis.

16 Jun 2008

Campaign says heart disease a top killer of women as well as men

A campaign by the Australian Heart Foundation is aiming to debunk the myth that heart disease is a medical condition that primarily affects men.

16 Jun 2008

Nanoparticles trigger built-in cell-death signal to overcome drug resistance

One of the most vexing problems in treating cancer is the propensity of tumors to develop resistance to a wide range of anticancer drugs. Over 70 percent of ovarian cancer patients, for example, have drug-resistant tumors at the time of their initial diagnosis, and virtually all patients who relapse have drug-resistant tumors.

15 Jun 2008

Anti-estrogen drug therapy reduces risk of invasive breast cancer in older women

New analysis of a drug approved for osteoporosis prevention and treatment has provided definitive evidence that the medication is also effective as a breast cancer preventative for certain cancers.

11 Jun 2008

Reduced incidence of invasive breast cancer with Raloxifene among women at increased coronary risk

Women who took raloxifene were less likely to develop invasive estrogen-receptor (ER) positive breast cancer compared with women who did not, according to data from a randomized controlled trial published online June 10 in the Journal of the National Cancer Institute. The drug did not reduce the risk of non-invasive cancer or invasive ER-negative cancers.

11 Jun 2008

The risk of death by age, sex, and smoking status in the U.S.

Researchers have updated charts that show an American's risk of dying from a given cause over the next ten years, based on age, sex, and smoking status. The charts will be published online June 10 in the Journal of the National Cancer Institute.

11 Jun 2008

Sunshine vitamin protect against heart attacks

In a study by researchers from the Harvard School of Public Health and Brigham and Women's Hospital in Boston, it has been found that men with low levels of vitamin D have an increased risk for heart attacks.

10 Jun 2008

Study finds wide racial, geographic health care disparities among Medicare beneficiaries

Race and place of residence can have a significant effect on the quality of care a Medicare beneficiary receives, according to a report released Thursday by the Robert Wood Johnson Foundation, the New York Times reports.

8 Jun 2008

BN ImmunoTherapeutics starts clinical trials with prostate cancer vaccine

BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.

4 Jun 2008

New 'Track Your Drinking' Google gadget

If you find it difficult to keep track of just how many glasses of wine you've consumed during the week, help is at hand thanks to Cancer Research UK.

3 Jun 2008

Bavarian Nordic enters trials with prostate cancer vaccine

Bavarian Nordic's subsidiary, BN ImmunoTherapeutics has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.

3 Jun 2008

Paclitaxel Poliglumex/Capecitabine regimen well tolerated and active in metastatic breast cancer

At the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO), data were presented from a phase II investigator-sponsored trial paclitaxel poliglumex (Opaxio, CT-2103) in combination with capecitabine in first-line treatment of patients with metastatic breast cancer (MBC).

3 Jun 2008

By 2024 one in seven women will be diagnosed with breast cancer

Experts in Britain are predicting that by 2024 one in seven women will be diagnosed with breast cancer if there is not an improvement in public health trends.

2 Jun 2008

Improving cancer diagnosis and support services for Asian patients

There is a need to remove the major ethnic inequalities which still exist in access to cancer services and outcomes, according to the latest edition of Science & Public Affairs.

2 Jun 2008

Study looks at the role of metformin as possible anti-tumor agent

Metformin, the common first-line drug for type 2 diabetes, may be effective in increasing pathologic complete response rates in diabetic women with early stage breast cancer who took the drug during chemotherapy prior to having surgery, paving the way for further research of the drug as a potential cancer therapy, according to researchers at The University of Texas M. D. Anderson Cancer Center.

2 Jun 2008

New breast cancer drug combo shrinks aggressive tumours

An international trial of a new breast cancer drug has shown the drug is able to shrink tumours caused by one of the most aggressive forms of the disease.

2 Jun 2008

Peregrine Pharmaceuticals updates on Bavituximab breast cancer study

Peregrine Pharmaceuticals, Inc. has announced that results from a Phase I clinical trial of its lead anti-phosphatidylserine (anti-PS) antibody bavituximab in combination with chemotherapy in patients with advanced cancer were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting.

2 Jun 2008

BiPar Sciences presents data for novel DNA repair inhibitor

BiPar Sciences, Inc. today announced the results of first-in-human clinical studies of its lead product, BSI-201, in patients with solid tumors.

2 Jun 2008

Genta announces initial trial results for novel drug for bone disease

Genta Incorporated has announced the release of final results from the Company's Phase 1 clinical trial of G4544, a proprietary small molecule that is intended as a treatment for diseases associated with accelerated bone loss. Results showed that the drug was very well-tolerated, and that blood levels were achieved in a range that is known to be clinically bioactive. The data were featured in a poster session at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago on Saturday, May 31, 2008.

2 Jun 2008